Dashboard PDUFA PDUFA History Dilution Watch Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Track MEDP with free AI briefings, catalyst countdowns, and dilution alerts.

MEDP · Medpace Holdings, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$502.7M Cash on Hand

CF+ Cash Runway

Follow MEDP by email Get an email when MEDP pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about MEDP, unsubscribe in one click. Privacy

🧪 Trial & FDA Catalysts

Jan 2027 · Phase 3 · Recruiting · Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bem
Registry primary completion date, not a results date
Aug 2027 · Phase 3 · Recruiting · Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurr
Registry primary completion date, not a results date
Oct 2027 · N/A · Recruiting · Study of the Shockwave Medical SkyRunner Carotid Intravascular Lithotripsy (IVL) System fo
Registry primary completion date, not a results date
Nov 2027 · Phase 1/2 · Recruiting · The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
Registry primary completion date, not a results date
Dec 2027 · Phase 1/2 · Recruiting · 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metas
Registry primary completion date, not a results date
Dec 2027 · N/A · Upcoming Trial · Study of the Shockwave Medical SkyRunner Carotid Intravascular Lithotripsy (IVL) System fo
Registry primary completion date, not a results date

📊 Drug Pipeline

Drug	Indication	Most advanced trial	Status
Invimestrocel	Ischemic Stroke	Phase 3 · NCT03545607	Terminated
Lerodalcibep	Familial Hypercholesterolemia - Heterozygous	Phase 3 · NCT07102511	Enrolling by invitation
TNX-103	Pulmonary Hypertension	Phase 3 · NCT05983250	Active not recruiting
Investigator's choice	HSV Infection	Phase 3 · NCT03073967	Completed
Etripamil Test Dose	Paroxysmal Supraventricular Tachycardia	Phase 3 · NCT03464019	Terminated
Etripamil NS 70 mg	Paroxysmal Supraventricular Tachycardia	Phase 3 · NCT03635996	Terminated
Dalcetrapib	Acute Coronary Syndrome	Phase 3 · NCT02525939	Completed
Cefepime-zidebactam (FEP-ZID)	Complicated Urinary Tract Infection	Phase 3 · NCT04979806	Completed
Pritelivir (AIC316)	HSV Infection	Phase 3 · NCT03073967	Completed
Rugonersen	Angelman Syndrome	Phase 3 · NCT07605429	Recruiting
Sevasemten	Becker Muscular Dystrophy	Phase 2 · NCT06066580	Enrolling by invitation
Dapolsertib	Acute Myeloid Leukemia	Phase 1/2 · NCT03008187	Completed
Levosimendan	Hypertension Pulmonary Secondary Heart Failure	Phase 2 · NCT03624010	Completed
RAD101 (18F-FPIA)	Brain Metastases From Solid Tumors	Phase 2 · NCT06777433	Active not recruiting
Tomivosertib	Non-small Cell Lung Cancer	Phase 2 · NCT04622007	Unknown
ETC-1002	Hypercholesterolemia	Phase 2 · NCT02178098	Completed

Also used in these trials (approved or third-party drugs, not MEDP's own candidates): Spinosad, Inclisiran, Etripamil, Meropenem, Pembrolizumab, Pemetrexed Disodium, Triamcinolone Acetonide Extended-Release Injectable, Valacyclovir, Supra-pharmacologic Dexamethasone Sodium Phosphate AVM0703, Avacopan, Toripalimab, Tocilizumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

MEDP holds $502.7M in cash and short-term investments (as of Jun 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

No operating cash burn in latest filings

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MEDP files for a raise →

Get the full MEDP picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MEDP and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z